Durable Antitumor Activity in ccRCC With Combination Belzutifan/Cabozantinib

“Belzutifan plus cabozantinib continue to show durable anti-tumor activity in patients with clear cell RCC who are treatment naïve or previously treated,” said Toni K. Choueiri, MD.

Related Keywords

Spain ,Madrid ,France ,Massachusetts ,United States ,Dana Farber Cancer Institute ,Paris ,France General ,Boston ,Nat Genet ,Tonik Choueiri ,Genitourinary Oncology Disease Center ,European Society For Medical Oncology ,Harvard Medical School ,Lank Center ,European Society Of Medical Oncology ,International Metastatic ,Database Consortium ,Medical Oncology ,Annual Congress ,Genitourinary Oncology ,European Society ,Esmo 2023 ,Nrcc ,Nccrcc ,Clear Cell Rcc ,Clear Cell Renal Carcinoma ,Kidney Cancer ,